Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO) and part of Piramal Pharma Ltd. (PPL), is strengthening its decarbonization efforts with the addition of a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, UK.
The solar plant, scheduled to begin operations in the first quarter of 2027, is expected to generate approximately 3,950 MWh of renewable electricity annually, meeting around 22% of the site’s annual electricity demand.
The installation will comprise around 6,200 solar panels spread across 16 acres, and have the capacity to produce enough clean electricity to power approximately 1,460 UK homes annually. The project is being developed under a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited (Alight), a solar developer and independent power producer.
According to the company, the project will enable the Morpeth site to avoid an estimated 20,000 tonnes of CO₂ equivalent emissions over 25 years.
The new plant will provide renewable energy directly to the site through a behind-the-meter setup. The project forms part of Piramal Pharma’s broader sustainability strategy and supports its target of reducing Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030.
“At Piramal Pharma Solutions, we integrate sustainability principles into every operation and decision across our global network,” said Frank Bugg, senior vice president, UK & Europe Operations and managing director, Piramal Pharma Solutions.
“We are excited to advance our commitment to decarbonization and renewable energy with our partner Alight, bringing new value to our customers and shareholders worldwide,” he added.
Rob Stait, managing director, Behind the Meter at Alight, said businesses across the UK are looking for practical ways to lower emissions, strengthen energy resilience, and manage long-term energy costs. “This project with Piramal Pharma shows how onsite solar can deliver all three,” he said.
